Neuronetics, Inc. (STIM)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$2.88+5.88%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · STIM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -70.5% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 10.5% |
Growth built into the price is above our model estimate.
The price assumes 81.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
STIM — CFO transition
Dated 2026-08-17
CFO — Nir Naor: The filing primarily documents the formalization of Nir Naor's role as CFO and Corporate Secretary, while noting the orderly transition of Francis Brown III to a consultant role rather than a sudden departure.
Why it matters: Higher expenses may hurt profits and cash flow.
Worry ifOperating expenses were over $100 million for the full year 2026.
Less concerning ifOperating expenses were below $100 million for the full year 2026.
Why it matters: Further policy changes could increase patient access and drive revenue growth.
Supportive ifOptum/UHC/UBH made new policy changes. These changes help more people access NeuroStar Advanced Therapy.
Worry ifOptum/UHC/UBH did not announce new policy changes. This means access to NeuroStar Advanced Therapy stays the same.
Why it matters: Good cost management can make finances stronger. It also helps meet growth goals.
Supportive ifThe company announced it has reduced its workforce. This fits with plans to cut costs.
Worry ifThere has been no progress on reducing the workforce.
Why it matters: The new CFO's plans may change how money is managed and how well the company runs.
Watch forThe new CFO made positive comments about financial plans and cash flow improvements.
Also watch forThere are negative reports or worries about money management with the new CFO.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$373 on $10,000 · ±3.7% | How much price usually moves either way. |
| Bad day | $1,032 loss on $10,000 · 10.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,802 loss on $10,000 · 68.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This report will show details about revenue and margins. It will also show overall performance.
Watch forEarnings report shows revenue and margins meeting or exceeding targets.
Also watch forThe earnings report shows big misses on revenue and margins.
Why it matters: More access can lead to increased patient volume and revenue growth for Neuronetics.
Supportive ifNew policy changes let more healthcare providers use NeuroStar TMS.
Worry ifNo new policy changes or setbacks in expanding access to TMS treatments.
Why it matters: Meeting this growth target shows the company is on track to reach its annual revenue goal.
Supportive ifQ3 revenue growth reported at 5% or higher compared to Q3 2025.
Worry ifQ3 revenue growth reported below 5% compared to Q3 2025.
Why it matters: Keeping this margin range is important for making money. It shows how well the company runs.
Supportive ifGross margin reported between 47% and 50% for Q3 2026.
Worry ifGross margin reported below 47% for Q3 2026.
Why it matters: Finishing this cut can lower costs. It can also make operations run better.
Supportive ifThe company plans to finish workforce cuts by mid-2026.
Worry ifThe company has not announced the end of workforce cuts by mid-2026.
Why it matters: More policy changes can increase patient access and drive revenue growth.
Supportive ifNew policies are now in place. They will help more people access NeuroStar Advanced Therapy.
Worry ifNo new policy changes announced that expand access by the end of 2026.